Scholarlink

Introduction <p>Patients with BRAF V600E-mutated/microsatellite stable (MSS) metastatic colorectal cancer (mCRC) are associated with a poor prognosis. Backline treatment has minimal efficacy. Multi-target inhibitors of the RAS-RAF-MEK signaling pathway combined with PD-1 monoclonal antibody may be a promising strategy for BRAF V600E-mutated mCRC.</p> Methods <p>This prospective phase I trial enrolled patients to explore tolerability and safety of the VCC regimen in previously treated patients with BRAF V600E-mutated/MSS mCRC. Enrolled patients treated with VCC therapy every 2 weeks (cetuximab 500mg/m<sup>2</sup>; camrelizumab 200&#xa0;mg; vemurafenib 960&#xa0;mg orally once daily). Adverse events and efficacy were monitored and recorded throughout the administration and follow-up period.</p> Results <p>This trial enrolled 12 eligible patients. Total 2 patients had DLT: one had grade 3 thrombocytopenia and immune myocarditis, another had grade 3 vaginal bleeding. Adverse events (AEs) of grade 3 or higher occurred in 50% of patients. Grade 3 AEs were mainly drug-related fever (25.0%), drug-related rash (16.7%). Median overall survival (OS) and PFS were 7.19 months and 3.47 months, respectively. The ORR and DCR were 33.3% and 66.7%. One patient achieved CR. three patients achieved PR. An abnormal CD4/CD8 ratio was associated with a higher risk of progression. Different efficacy of VCC regimen may be attributed to the difference in tumor immune environment.</p> Conclusions <p>A combination of vemurafenib, cetuximab combined with camrelizumab exhibited manageable adverse reactions and efficacy in BRAF V600E-mutated/MSS patients with metastatic colorectal cancer who progressed after standard treatment. This is a pilot study and a larger phase II trials is planned to validate the findings. (ClinicalTrials.gov ID: NCT05019534).</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Vemurafenib, cetuximab and camrelizumab in BRAF V600E-mutated/MSS metastatic colorectal cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月12日

查看全文
  • Gui-Xia Wei,
  • Yu-Wen Zhou,
  • Peng Cao,
  • Wei-Bing Leng,
  • Li Wang,
  • Jie Tang,
  • Meng Qiu

摘要

Introduction

Patients with BRAF V600E-mutated/microsatellite stable (MSS) metastatic colorectal cancer (mCRC) are associated with a poor prognosis. Backline treatment has minimal efficacy. Multi-target inhibitors of the RAS-RAF-MEK signaling pathway combined with PD-1 monoclonal antibody may be a promising strategy for BRAF V600E-mutated mCRC.

Methods

This prospective phase I trial enrolled patients to explore tolerability and safety of the VCC regimen in previously treated patients with BRAF V600E-mutated/MSS mCRC. Enrolled patients treated with VCC therapy every 2 weeks (cetuximab 500mg/m2; camrelizumab 200 mg; vemurafenib 960 mg orally once daily). Adverse events and efficacy were monitored and recorded throughout the administration and follow-up period.

Results

This trial enrolled 12 eligible patients. Total 2 patients had DLT: one had grade 3 thrombocytopenia and immune myocarditis, another had grade 3 vaginal bleeding. Adverse events (AEs) of grade 3 or higher occurred in 50% of patients. Grade 3 AEs were mainly drug-related fever (25.0%), drug-related rash (16.7%). Median overall survival (OS) and PFS were 7.19 months and 3.47 months, respectively. The ORR and DCR were 33.3% and 66.7%. One patient achieved CR. three patients achieved PR. An abnormal CD4/CD8 ratio was associated with a higher risk of progression. Different efficacy of VCC regimen may be attributed to the difference in tumor immune environment.

Conclusions

A combination of vemurafenib, cetuximab combined with camrelizumab exhibited manageable adverse reactions and efficacy in BRAF V600E-mutated/MSS patients with metastatic colorectal cancer who progressed after standard treatment. This is a pilot study and a larger phase II trials is planned to validate the findings. (ClinicalTrials.gov ID: NCT05019534).